Antineoplastic agents. 550. Synthesis of 10b(S)-epipancratistatin from (+)-narciclasine

Journal of Natural Products

Volumn 70, Issue 3, 2007, Pages 417-422

  Pettit, George R ^a   Melody, Noeleen ^a   Herald, Delbert L ^a   Knight, John C ^a   Chapuis, Jean Charles ^a  

^a ARIZONA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

10B 1,2,3,4 TETRA O ACETYLPIPANCRATISTATIN; 10B 2,3,4 TRI O ACETYLPANCRATISTATIN; 10B EPIPANCRTISTATIN; 10B HYDROXY 2,3,4 TRI O ACETYLPANCRATISTATIN; 10B HYSDROXY 1,2,3,4,7 PENTA O ACETYLPANCRATISTATIN; 2,3,4 TRI O ACETYLNARCICLASINE; ANTINEOPLASTIC AGENT; NARCISCLASINE; PLANT EXTRACT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG DOSE; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; NARCISSUS; NONHUMAN;

AMARYLLIDACEAE ALKALOIDS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MOLECULAR STRUCTURE; NARCISSUS; PHENANTHRIDINES; PLANTS, MEDICINAL; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

NARCISSUS;

EID: 34247169948     PISSN: 01633864     EISSN: None     Source Type: Journal    
DOI: 10.1021/np068046e     Document Type: Article

References (29)

1. For the preceding part in this series, see Antineoplastic Agents 549: Pinney, K. G.; Jelinek, C.; Edvardsen, K.; Chaplin, D. J.; Pettit, G. R. Anticancer Agents Nat. Prod. 2005, 23-46.
2. (a) Pettit, G. R.; Gaddamidi, V.; Cragg, G. M.; Herald, D. L.; Sagawa, Y. J. Chem. Soc., Chem. Commun. 1984, 1693-1694.
3. (b) Pettit, G. R.; Gaddamidi, V.; Herald, D. L.; Singh, S. B.; Cragg, G. M.; Schmidt, J. M. J. Nat. Prod. 1986, 49, 995-1002.
4. (c) Pettit, G. R.; Melody, N.; Herald, D. L. J. Nat. Prod. 2004, 67, 322-327.
5. (d) Pettit, G. R.; Ducki, S.; Orr, B. Antineoplastic Agents 453. Synthesis of Pancratistatin Prodrugs. Anti-Cancer Drug Des. 2000, 15, 389-396.
6. (e) Pettit, G. R.; Freeman, S.; Simpson, M. J.; Thompson, M. A.; Boyd, M. R.; Williams, M. D.; Pettit, G. R., III; Doubek, D. L. Anticancer Drug Des. 1995, 10, 243-250.
7. Bibby, M. C.; Holwell, S. E.; Pettit, G. R. Anti-Vascular & Anti-Tumour Effects of the Novel Agent Pancratistatin Phosphate. Abstract. Biological Basis for Antiangiogenic Therapy Conference, Milan, Italy, November 8-10, 1999.
8. Gabrielsen, B.; Monath, T. P.; Huggins, J. W.; Kefauver, D. F.; Pettit, G. R.; Groszek, G.; Hollingshead, M.; Kirsi, J. J.; Shannon, W. M.; Schubert, E. M.; Dare, J.; Ugarkar, B.; Ussery, M. A.; Phelan, M. J. J. Nat. Prod. 1992, 55, 1569-1581.
9. Ouarzane-Amara, M.; Franetich, J-F.; Mazier, D.; Pettit, G. R.; Meijer, L.; Doerig, C.; Desportes-Livage, I. Antimicrob. Agents Chemother. 2001, 45, 3409-3415.
10. Khan, P.; Abbas, S.; Pettit, G. R.; Caffrey, R.; Megram, V.; McGown, A. J. Chromatogr. B 1999, 726, 249-254.
11. For leading references, refer to: Pettit, G. R.; Melody, N.; Herald, D. H. J. Org. Chem. 2001, 66, 2583-2587.
12. (a) Hudlicky, T.; Rinner, U.; Gonzalez, D.; Akgun, H.; Schilling, S.; Siengalewicz, P.; Martinot, T. A.; Pettit, G. R. J. Org. Chem. 2002, 67, 8726-8743.
13. (b) McNulty, J.; Mao, J.; Gibe, R.; Mo, R.; Wolf, S.; Pettit, G. R.; Herald, D. L.; Boyd, M. R. Bioorg. Med. Chem. Lett. 2001, 11, 169-172.
14. (c) Pettit, G. R.; Melody, N.; Herald, D. L.; Schmidt, J. M.; Pettit, R. K.; Chapuis, J.-C. Heterocycles 2002, 56, 139-155.
15. (a) Barton, D. H. R; McCombie, S. W. J. Chem. Soc., Perkin Trans. 1 1975, 1574-1585.
16. (b) Barton, D. H. R.; Subramanian, R. J. Chem. Soc, Chem. Comm. 1976, 867-868.
17. (c) Barton, D. H. R.; Hartwig, W.; Hay Motherwell, R. S.; Motherwell, W. B.; Stange, A. Tetrahedron Lett. 1982, 23, 2019-2022.
18. Pullukat, T. J.; Urry, G. Tetrahredron Lett. 1967, 21, 1953-1954.
19. Kutney, J. P.; Honda, T.; Kazmaier, N. J. L.; Worth, B. R. Helv. Chim. Acta 1980, 61, 366-374.
20. Dolan, S. C.; Macmillian J. J. Chem. Soc., Chem. Commun. 1985, 1588-1589.
21. (a) Rinner, U.; Siengalewicz, P.; Hudlicky, T. Org. Lett. 2002, 4, 115-117.
22. (b) Pettit, G. R.; Du, J.; Pettit, R. K.; Richert, L. A.; Hogan, F.; Mukku, V. J. R. V.; Hoard, M. S. J. Nat. Prod. 2006, 69, 804-806.
23. (a) Okamoto, T.; Torii, Y.; Isogai, Y. Chem. Pharm. Bull. 1968, 16, 1860-1864.
24. (b) Mondon, A.; Krohn, K. Chem. Ber. 1975, 108, 445-463.
25. Blessing, R. Acta Crystallogr. 1995, A51, 33-8.
26. SHELXTL-Version 5.1, an integrated suite of programs for the determination 6f crystal structures from diffraction data; Bruker AXS, Inc.: Madison, WI, 1997. This package includes, among others, XPREP (an automatic space group determination program), SHELXS (a structure solution program via Patterson or direct methods), and SHELXL (structure refinement software).
27. Monks, A.; Scudiero, D.; Skehan, P.; Shoemaker, R.; Paul, K.; Vestica, D.; Hose, C.; Langley, J.; Cronise, P.; Vaigro-Wolff, A. J. Natl. Cancer Inst. 1991, 83, 757-755.
28. Suffness, M.; Douros, J. In Methods in Cancer Research, Vol. XVI, Cancer Drug Development Part A.; Devita, V. T., Jr., Bush, H., Eds.; Academic Press: New York, 1979; pp 73-126.
29. Crystallographic data for the structures reported in this paper have been deposited as CIF files with the Cambridge Crystallographic Data Centre. Copies of the data can be obtained, free of charge, on application to the Director, CCDC, 12 Union Road, Cambridge CB2 1EZ, UK [fax: +44 (0) 223-336033 or e-mail: deposit@ccdc.cam.ac.uk].